GLP-1 Medications: What Ozempic Is Actually Doing to Your Body

Ozempic and Wegovy aren't just weight loss drugs. The 2024 SELECT trial showed 20% fewer heart attacks. The FLOW trial was stopped early due to kidney prot

Key Findings

Key Nutrients

The Bottom Line

GLP-1 receptor agonists are genuinely novel in medicine — they work on biology most drugs don't touch. The cardiovascular and kidney data is compelling and real. But so are the practical considerations: muscle loss, nutrient depletion from reduced food intake, and what happens when you stop. Understanding the full picture is what separates a good outcome from a complicated one.

Related Topics

More Health Intelligence